Search Within

Matthew David Hellmann

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (43)
  2. Meeting Abstract (25)
  3. Research Letter (1)
Groups
  1. Department of Medicine (69)
  2. Human Oncology and Pathogenesis Program (69)
  3. Solid Tumor Oncology Division (69)
  4. Thoracic Oncology (69)
  5. GSK Faculty (68)
  6. Department of Pathology and Laboratory Medicine (60)

More Groups

People
  1. Marc Ladanyi (49)
  2. Charles Rudin (42)
  3. Gregory Riely (34)
  4. Mark Kris (32)
  5. Maria Arcila (28)
  6. Hira Rizvi (27)

More People

Years
  1. 2024 (3)
  2. 2023 (7)
  3. 2022 (10)
  4. 2021 (4)
  5. 2020 (7)
  6. 2019 (12)

More Years

Publications
  1. Journal of Clinical Oncology (17)
  2. Journal of Thoracic Oncology (8)
  3. Clinical Cancer Research (7)
  4. Annals of Oncology (6)
  5. JCO Precision Oncology (4)
  6. Nature (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (21)
  2. American Association for Cancer Research (12)
  3. Nature Publishing Group (10)
  4. Elsevier Inc. (8)
  5. Oxford University Press (8)
  6. Cell Press (3)

More Publishers

Results (69)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Harnessing clinical sequencing data for survival stratification of patients with metastatic lung adenocarcinomas
    Journal Article

    Shen, R.; Martin, A.; Ni, A.; Hellmann, M.; Arbour, K. C.; Jordan, E.; Arora, A.; Ptashkin, R.; Zehir, A.; Kris, M. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez-Vega, F.; Li, B. T.; Drilon, A.; Kris, M. G.; Rudin, C. M.; Schultz, N.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS)
    Meeting Abstract

    Xu, C.; Myers, M.; Buonocore, D. J.; Razavi, P.; Shen, R.; Lai, W. C. V.; Smyth, L. M.; Zheng, T.; Ni, A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC)
    Meeting Abstract

    Voss, M. H.; Novik, J. B.; Hellmann, M. D.; Ball, M.; Hakimi, A. A.; Miao, D.; Margolis, C.; Horak, C.; Wind-Rotolo, M.; De Velasco, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas
    Meeting Abstract

    Shen, R.; Martin, A.; Ni, A.; Hellmann, M. D.; Jordan, E.; Arora, A.; Ptashkin, R.; Zehir, A.; Kris, M. G.; Arbour, K. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC
    Meeting Abstract

    Rizvi, H.; Plodkowski, A. J.; Tenet, M.; Halpenny, D.; Long, N.; Sauter, J. L.; Sanchez-Vega, F.; Chatila, W. K.; Schultz, N.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • VISTA is highly expressed in malignant pleural mesothelioma (MPM) and independent of PD-L1 expression
    Meeting Abstract

    Zauderer, M.; Muller, S.; Lai, W.; Ni, A.; Jungbluth, A.; Ginsberg, M.; Daly, R.; Hellmann, M.; Ladanyi, M.; Sauter, J.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations
    Meeting Abstract

    Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
    Journal Article

    Yu, H. A.; Suzawa, K.; Jordan, E.; Zehir, A.; Ni, A.; Kim, R.; Kris, M. G.; Hellmann, M. D.; Li, B. T.; Somwar, R.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save